Next anticipated milestones
EU: Additional agreements around reimbursement / Post approval study to be completed by 2025
Commercialization ongoing based on approval.
- Results from the Phase 1 study have been published, Winstedt el al. (2015) PLOS ONE 10(7)
- Lorant et al, American Journal of Transplantation and 03+04 studies (Jordan et al New England Journal of Medicine)
- The EU Commission has granted conditional approval for imlifidase in highly sensitized kidney transplant patients. As part of the conditional approval Hansa has committed to do a post-approval study